Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;17(2):144-148.
doi: 10.2174/1574884716666210215104540.

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance

Tomohito Wakabayashi  1 , Takahiro Nakatsuji  1 , Hiroko Kambara  1 , Iku Niinomi  1 , Saki Oyama  1 , Ayaka Inada  1 , Sayaka Ueno  1 , Mayako Uchida  1 , Kazunori Iwanaga  1 , Tatsuya Iida  1 , Keiko Hosohata  1
Affiliations

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance

Tomohito Wakabayashi et al. Curr Rev Clin Exp Pharmacol. 2022.

Abstract

Background: Several studies reported that abnormal behavior was noted in pediatric patients receiving several drugs, including neuraminidase inhibitors (NIs). However, the information on drugs associated with abnormal behavior in a real-world setting remains limited. The purpose of this study was to clarify the drugs associated with abnormal behavior using a spontaneous reporting system database.

Methods: We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency were analyzed, and the reporting odds ratio at 95% confidence interval were calculated.

Results: A total of 1,144 reports of abnormal behavior were identified. The signals were detected through the association of 4 neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) with the abnormal behaviour. These signals were stronger for oseltamivir than other neuraminidase inhibitors. The signals were also detected for acetaminophen and montelukast.

Conclusion: Our results should be able to raise physicians' awareness of drugs associated with abnormal behavior, but further investigation of these medications is warranted.

Keywords: Adverse events; Japanese Adverse Drug Event Report (JADER) database; reporting odds ratio; spontaneous reporting system.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Similar articles

See all similar articles

Cited by

References

    1. Toovey S., Rayner C., Prinssen E., et al. Assessment of neuropsy- chiatric adverse events in influenza patients treated with oselta- mivir: a comprehensive review. Drug Saf. 2008;31(12):1097–1114. doi: 10.2165/0002018-200831120-00006. - DOI - PubMed
    1. Nakano T., Okumura A., Tanabe T., et al. Safety evaluation of la- ninamivir octanoate hydrate through analysis of adverse events re- ported during early post-marketing phase vigilance. Scand. J. Infect. Dis. 2013;45(6):469–477. doi: 10.3109/00365548.2012.763104. - DOI - PubMed
    1. Toovey S., Prinssen E.P., Rayner C.R., et al. Post-marketing assess- ment of neuropsychiatric adverse events in influenza patients trea- ted with oseltamivir: an updated review. Adv. Ther. 2012;29(10):826–848. doi: 10.1007/s12325-012-0050-8. - DOI - PubMed
    1. Yorifuji T., Suzuki E., Tsuda T. Oseltamivir and abnormal behavi- ors: true or not? Epidemiology. 2009;20(4):619–621. doi: 10.1097/EDE.0b013e3181a3d3f6. - DOI - PubMed
    1. Mahé J., de Campaigno E.P., Chené A.L., Montastruc J.L., Despas F., Jolliet P. Pleural adverse drugs reactions and protein kinase inhi- bitors: Identification of suspicious targets by disproportionality analysis from VigiBase. Br. J. Clin. Pharmacol. 2018;84(10):2373–2383. doi: 10.1111/bcp.13693. - DOI - PMC - PubMed